Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

NCT05529355 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Envafolimab plus Endostar and S-1
DRUG: Envafolimab plus Endostar
DRUG: Envafolimab plus S-1

Sponsor

Anhui Chest Hospital